Table 5.

The Significant Alternative Splicing Events by Comparing Depletion of HNRNPM With Wild-type HCC Cells

Gene name	AS type	P value	FDR	Group 1 value	Group 2 value	Group difference
APLP2	SE	0	0	0.691–0.613	0.239–0.243	0.411
DNMT3B	SE	1.54E−12	7.13E−09	1.0–1.0	0.116–0.0	0.942
PBRM1	A3SS	8.74E−11	3.10E−08	0.0–0.0	1.0–0.817	−0.908
THNSL2	SE	2.15E−10	7.96E−07	1.0–1.0	0.0–0.111	0.945
PRR7-AS1	SE	5.01E−10	1.54E−06	0.0–0.0	1.0–1.0	−1
RP5-1185I7.1	SE	1.14E−09	3.00E−06	1.0–1.0	0.333–0.13	0.768
LINC00958	SE	1.55E−09	3.19E−06	1.0–1.0	0.0–0.0	1
CCDC18	SE	1.47E−09	3.19E−06	0.0–0.0	1.0–1.0	−1
MBD2	A3SS	1.71E−05	0.00372	0.771–1.0	0.259–0.278	0.617
WDSUB1	MXE	1.71E−09	3.72E−06	1.0–1.0	0.0–0.0	1
CYP2C18	SE	2.59E−09	4.36E−06	0.0–0.0	1.0–1.0	−1
GMPR2	SE	2.40E−09	4.36E−06	1.0–0.6	0.0–0.0	0.8
ZNF107	SE	4.09E−09	6.31E−06	0.0–0.111	1.0–0.714	−0.801
TEX41	MXE	1.11E−08	8.07E−06	0.0–0.0	1.0–1.0	−1
U2AF1L5	MXE	1.11E−08	8.07E−06	0.0–0.0	1.0–1.0	−1
YWHAZ	MXE	2.62E−08	1.15E−05	0.47–0.516	0.662–0.653	−0.164
FAM171A1	MXE	2.60E−08	1.15E−05	0.0–0.0	0.778–0.583	−0.68
RP11-762I7.5	SE	8.79E−09	1.25E−05	1.0–1.0	0.0–0.0	1
PI4KB	SE	1.38E−08	1.77E−05	1.0–0.933	0.565–0.467	0.451
PATZ1	SE	1.44E−08	1.77E−05	1.0–1.0	0.133–0.176	0.846
SMG1P3	SE	2.47E−08	2.86E−05	1.0–1.0	0.162–0.279	0.779
BID	SE	2.66E−08	2.90E−05	0.443–0.511	0.88–0.82	−0.373
TNFSF13	SE	3.93E−08	4.04E−05	0.269–0.0	1.0–1.0	−0.865
BTN2A2	MXE	1.62E−07	5.90E−05	1.0–1.0	0.5–0.286	0.607
GLDN	MXE	2.28E−07	7.10E−05	1.0–1.0	0.504–0.245	0.625
SMARCAD1	A3SS	4.78E−07	8.48E−05	0.771–1.0	0.259–0.278	0.617
CTTN	SE	1.16E−07	0.000107	0.921–0.88	0.752–0.78	0.135
POGZ	SE	1.12E−07	0.000107	0.963–1.0	0.802–0.675	0.243
MARCH7	SE	1.24E−07	0.000109	1.0–1.0	0.0–0.476	0.762

A3SS, Alternative 3′ splicing site; AS, alternative splicing; HCC, hepatocellular carcinoma; HNRNPM, heterogeneous nuclear ribonucleoprotein M; MXE, mutually exclusive exon; SE, skipped exon.